Frontiers in Immunology (Oct 2022)

Pan-cancer analyses of classical protein tyrosine phosphatases and phosphatase-targeted therapy in cancer

  • Tao Wang,
  • Xinlei Ba,
  • Xiaonan Zhang,
  • Xiaonan Zhang,
  • Na Zhang,
  • Guowen Wang,
  • Bin Bai,
  • Tong Li,
  • Jiahui Zhao,
  • Yanjiao Zhao,
  • Yang Yu,
  • Bing Wang

DOI
https://doi.org/10.3389/fimmu.2022.976996
Journal volume & issue
Vol. 13

Abstract

Read online

Protein tyrosine phosphatases function in dephosphorylating target proteins to regulate signaling pathways that control a broad spectrum of fundamental physiological and pathological processes. Detailed knowledge concerning the roles of classical PTPs in human cancer merits in-depth investigation. We comprehensively analyzed the regulatory mechanisms and clinical relevance of classical PTPs in more than 9000 tumor patients across 33 types of cancer. The independent datasets and functional experiments were employed to validate our findings. We exhibited the extensive dysregulation of classical PTPs and constructed the gene regulatory network in human cancer. Moreover, we characterized the correlation of classical PTPs with both drug-resistant and drug-sensitive responses to anti-cancer drugs. To evaluate the PTP activity in cancer prognosis, we generated a PTPscore based on the expression and hazard ratio of classical PTPs. Our study highlights the notable role of classical PTPs in cancer biology and provides novel intelligence to improve potential therapeutic strategies based on pTyr regulation.

Keywords